Dyslipidemia

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Topline data from the pivotal Phase 3 trial show plozasiran met the primary endpoint of triglyceride-lowering in patients with the ultrarare genetic disease.

Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.

Blocking IL-33 production with statins may be an effective preventive strategy to suppress chronic inflammation and the development of certain cancers.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

Alirocumab added to high-intensity statin therapy did not further improve endothelial function in patients with acute myocardial infarction.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.

A new study found a greater PCSK9 is associated with a greater cutaneous melanoma risk.

ORION-8 demonstrates the consistent long-term efficacy and tolerability of twice-yearly inclisiran over a mean cumulative exposure of 3.7 years.

Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

Announced on May 22, 2024, the Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream to evaluate cardiovascular risk.

Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.

Study finds 2013 ACC/AHA guideline led to immediate improvements in optimal statin use for ASCVD patients and enhanced 5-year MACE survival for populations with ASCVD or diabetes in the US.

Transmasculine patients undergoing GAHT may experience adverse lipid profile changes, unlike transfeminine counterparts, which investigators say is cause for closer monitoring.

A systematic review and meta-analysis of 51 studies suggests elevated Lp(a) can help predict risk of premature atherosclerotic cardiovascular disease.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

A new study highlights the potential of lipoprotein apheresis for reducing cardiovascular events in patients with elevated Lp(a).

The final in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on treatment considerations and therapeutic options for elevated Lp(a).

Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

An analysis of NHANES found aspirin's benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.